michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, this is Mike. On the COVID cost, we said previously, and we haven't changed from that -- we spent about $50 million last year, and we're going to spend about $60 million this year, so up about $10 million. Now, the timing of that's a little different. It's going to be first half heavily weighted in 2021. A lot of that's the co-man costs we called out before. Kind of leading to your second question. Co-man was coming in the first quarter wasn't a full impact of the co-man costs as we ramped things up. So really the second quarter is where kind of every month, we'll have the full co-man costs. That's a little bit of the headwind in the second quarter. We talked about the first quarter, our consumer A&P was up around 17%. We're going to have another investment of A&P in the second quarter to drive sales as we said to -- again, that's part of the first half-second half story. So I think Q2 has a bit of a headwind from an expense perspective in a COVID and A&P cost perspective. And also the tax rates, they're going down to the EPS line.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you, Steve.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, Bobby, that's a really good question and we're trying to work through those answers ourselves. But Steve, why don't you, based on the most contemporary information we have, try to answer that question?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Okay, great. Fantastic. Thanks so much. I wanted to follow-up on the strength and the momentum you're seeing in international markets with, I think, first half revenue expected to be above first half of 2019 internationally. Obviously there were a number of headwinds in Europe that you cited. So, are we -- to read into that, that what you're seeing is just absolutely tremendous growth in Asia, a little more sluggish in Europe and you expect Europe to catch up in the back half of the year. I'm just wondering how we should think about those two regions relative to one another. Thanks.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thanks, Joanne. Thanks for the question. Listen, number one, we're very excited about the Pulse system, and we did receive CE Mark earlier, and we've been in doing, as we talked about clinical valuations in six European countries. We are, to your point, we're literally waiting day by day on the FDA 510(k) approval. That will then kick off the valuations that we'll schedule for the U.S. market. As we roll it out, it's really going to be relegated on Phase one, I would say, with Western Europe and U.S. We feel like we've got good demand. We've got good line of sight to delivering what we say we're going to deliver. And I've said all along with Pulse that we're being disciplined on how we roll it out.
We're making sure that we obviously have been building a pipeline to sell the product. We've been building flexibility and a portfolio of options to offer our customers. We want to make sure we in-service appropriately and install the system to actually do what we've talked about, which is participate in 100% of spine cases. So we're being very disciplined, but we feel very confident in how we roll the product out and what it represents for us going forward. From there, we'll start to move into other regional geographies over the 2022 and beyond. But as we look forward over the course of this year, really into Q-four, rolling through Q-three as clinical evaluations and looking to fully start to commercialize in the Q-four time frame.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, I'll take the second part of that first. There's clearly one large tenant, the one that's not renewing, that is implementing a significant work from home strategy. The other large tenant that we're renewing is not, and their contraction is less severe than we anticipated before the pandemic, which is good news for our shareholders. With regard to recycling those assets, we have always maintained that they're our future opportunity for recycling. We don't anticipate doing it this year in particular, because we need to renew those tenants or reestablish the occupancy that we're going to lose. But they are certainly candidates for recycling in future years.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi. Thanks. Good morning. Your 3Q revenues beat guidance by about $50 million, while your full year guidance increased by about $130 million at the midpoint. I know Appriss is adding $150 million in annual revenue. But how much of the increase in the guide above the 3Q outperformance is due to contributions from Appriss and other acquisitions versus improved assumed performance in 4Q with the underlying business?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Thank you. I'm looking at a table, I just would like you to comment on it. The S&P 500 is 23 times earnings. You are 3.6 times earnings. The S&P is 4 times book value. You're about 87% of book value. The S&P yields 1.55%. You yield 5.4%. The S&P is earning 23% on equity. And you're earning in the high 20s, call it 26% return on equity. What do you think the market is thinking about you and can you be more aggressive in capitalizing what seems to be a mispricing of our equity? I assume you would think your book value is real. So, you have the chance to buy it back at discount to book, which accretes the remaining shares. I think you started you whole buyback a number of years ago when the stock was close to $30. So, why aren't we not more aggressive? I understand the environment, but it seems to me, if they will forgive student debt, you're going to have a lot more cash to deal with.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Hi, Sanjit, it's good to hear from you. Well, first, let me just highlight, revenue is a lagging indicator in the fast model and basically represents activity in the last four quarters, maybe even further back. And that's why I made the statement that with billings growing at 25%, ARR, right in line with that, ultimately has to become the growth rate in revenue because it just naturally converts to revenue.
And with all these metrics pointing to that number, ultimately, that's going to work its way through revenue. For Q4, not yet, you know, basically in line with what we've been saying. But you can't have ARR growing at that rate without it finally working its way through revenue, which sometimes just takes longer than we all hope for it to be, but you obviously cannot expect the revenue to track exactly what happens in billings or ARR growth in any one quarter.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. I think based on what Roche has reported as to their overall revenues for Phesgo, they are not getting out the gate as fast as DARZALEX FASPRO. And I will say that DARZALEX FASPRO has exceeded our expectations with the speed of adoption in the United States. So we always expected for Phesgo focusing there that 2020 would be the initial couple of quarters while they get all of the key logistics in place. So things like working on reimbursement, getting on formularies, getting uploaded to the electronic medical records. And it was always our expectation that 2021 would be where we see Phesgo really starting that robust uptake. And so we're spending, I think, very nicely poised for that to see greater penetration in the U.S. as well as more revenues coming from Europe, which is now only beginning to launch. So Phesgo, this will be a good year, we believe, for strong growth there. DARZALEX FASPRO got out of the gate faster than I think any launch. I've personally seen. So they are going to continue that momentum as well and will be the dominant driver of our royalty revenues. But we're going to see a very nice contribution from Phesgo as it -- from the two dynamics I just mentioned though.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, we had a great success especially on the noninterest-bearing deposits. When we look at the composition of that, the increases we see in two types. One, from the institutional from CBG deposits as well as lots of retail deposit increase. And we believe that retail deposits is mainly coming from the government subsidize or PPP, those loans, maybe there is some temporary in nature, so there will be some run-off. I don't think there will be a dramatic run-off for those retail side. And going back to the CBG or institutional noninterest-bearing deposit, we see it's a very stable. So we do not expect a meaningful run-off for that institutional noninterest-bearing deposits. So both combined, we expect there might be some run-off, but we do not expect substantial reduction of our deposit that we grew for the last 18 months or so in the near future.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Who is it? I'm sorry, we didn't hear your name.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
No. We actually don't know actually who will be in attendance at the Type C meeting. We make requests, but you really never know until you actually attend the meeting. And we're not privy to or aware of what the FARA's activities are with respect to their interactions with FDA.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. I believe in my prepared remarks today, I commented that consumption in organic sales trends were pretty much the same at about 10% or so. And we saw the same thing more or less in the first quarter as well.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi guys. Thanks very much. Did you mention how much revenue impact you are seeing in the quarter? What -- are you unable to ship product? How much might that be? Just out of curiosity. And then I have a follow-up.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So I would -- first of all, I'd say that their -- sustainability, like many, is taken up in a lot of directions, more so that I think we would have -- certainly I would have said a year ago, etc. So there's a lot we're looking at that we never thought we would have before. And so even the word can is confusing at some point, so which is -- by the way, it's metal containers, and it really is it's more than cans. Today, not so much, but maybe in the future. And so I think the answer is yes, there are -- among the things, there are a few more on-the-go possibilities that are happening that we are looking at. But there's a lot -- in the metal world, you're right that, that is not quite a bit. So I think more of the ongoing solutions are probably going to be in other substrates like plastic, but there are some.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Good morning. Maybe some more granular questions. I'm not sure if I missed this, but the tax rate for this year looks pretty favorable. Can you walk through some of the moving parts there? It looks like you're benefiting from a particularly low tax rate.
What would you recommend we expect beyond the current year kind of on a more normalized basis?

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, I think there's a couple of elements on that. On the -- there is -- first on the pricing, one of the costs that we began to experience in the fourth quarter and are experiencing to start this year. And again, as Phil said, like logistics, it's pretty normal for us when our business inflects to go up as steel costs. That is an example. Though we typically do recover that through pricing mechanisms we have in our contracts and/or price increases that we'll pass through, but there's generally a little bit of a lag. So we would expect if that continues to strengthen, you would also start to see us pick up some recovery of that as the year goes on. So we do have the ability to do that as the year goes forward. From a contractual basis, again, a lot of our contracts were negotiated four, five months ago for this year, and I think we -- generally, there, we've got pricing mechanisms if costs go out of line, but we would generally be locked in on those prices for the year. We moved some prices up a little bit and some down a little bit. But we've been expecting flattish pricing for the year, and I think we'll deliver good results with that. But I guess the other final point I'd put just in there is well over half of our business is not contractually tied in any sort of way from a pricing standpoint, so we do have the ability as the year progresses if we have to, to do more in that area.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Great. Thanks guys. Another one on the competitive environment for advisors. How does what you're seeing in the marketplace today compared to history, I mean is this about as competitive as you've seen it or not necessarily more like middle of the road, I guess, that's the first part of the question and then second part of the question is are you a little surprised about how competitive is getting given where interest rates are?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. Hi.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah. No, I appreciate it. One thing I'll just -- I just want to sort of go back to our performance this quarter, and I know it's all sort of recovery driven. But I do think posting the industry's best margin very close to breakeven in a quarter that started with very thin demand and very poor pricing.
It just underscores the strength of the business and our ability to execute. And so we've got a lot of confidence as we go forward. I think, Dan, we laid out $265 million of cost reduction initiatives that we're well on our way to capturing. And then $300 million of revenue initiatives that we just talked about today.
Some of that was contemplated because we thought maybe the demand environment like passed down terms would be a little dampened coming out of COVID as it was in the last two big sort of industry downturns. And we wanted to be able to get back to pre-COVID margins irrespective of whether demand was down a bit. And it proves not to be down a bit, but it's just more upside for the company. And so I think those two, $565 million or so of improvement to the business over the next few years relative to our pre-COVID baseline, that's what's going to drive this ultimately.
We've got a great product. We have phenomenal employees, great customer service. We're on a good part of the country, a growing part of the country. So we're excited for things to stabilize, like Ben said, normalized business get back out there.
And we're ready for the recovery.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I'm doing well.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Hi, there. Thanks for letting me ask a follow-up. I have a question relating to the ICT business and whether you can give us any insight on what sort of return level you're targeting on your investment in the ICT business? I ask this because we don't have any visibility on profits at the moment. It's quite hard also to distinguish the level in investment. So it would be helpful to get your view, what you're targeting in the next year or two in terms of return on investment in that segment? Thank you.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes sure. Yes we actually, I would say that type of variance or bridge item probably will continue as we've mentioned in our full year guidance. We absolutely plan for higher IT strategic spend. We knew property insurance premiums were going up. And as well as long as 2021 played out like we expected, we would be back to accruing incentives at target versus or appropriately depending on our outlook for the business versus what we were doing last year where obviously there was weakness very specific to COVID. So, yes, I think I mentioned that our SG&A results while higher year-over-year in the first quarter were pretty much as expected. And so I'd expect that to continue generally through the year.

    Prediction (one of UP, DOWN, SAME): SAME